<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19950">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01834911</url>
  </required_header>
  <id_info>
    <org_study_id>L-10,830</org_study_id>
    <nct_id>NCT01834911</nct_id>
  </id_info>
  <brief_title>Effect of Tetrabenazine on Stroop Interference in HD</brief_title>
  <official_title>Effect of Tetrabenazine on Stroop Interference in Huntington Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve
      postural stability in Huntington disease (HD) patients as measured by computerized dynamic
      posturography testing. This study aims to elucidate whether partial dopaminergic depletion
      via low dose tetrabenazine has a similar effect on masking out of abnormal visual stimuli on
      the Stroop interference test.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Stroop Interference Score</measure>
    <time_frame>6 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants will have Stroop Visual Interference Scores measured while OFF tetrabenazine for at least 3 days. Two doses of 12.5 mg tetrabenazine will be subsequently administered: first dose just after the Stroop test and second dose 3 hours later. Stroop Visual Interference Scores will be measured again in the ON state, 6 hours after the initial OFF measurement.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>Tetrabenazine withdrawal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently taking the medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetrabenazine withdrawal</intervention_name>
    <description>Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.</description>
    <arm_group_label>Tetrabenazine withdrawal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of Huntington disease by movement disorders expert

          -  Patients currently taking tetrabenazine.

          -  Patients should not have taken dopamine receptor blocking medication for at least
             three days

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robert Fekete, MD</last_name>
    <phone>9145944293</phone>
    <email>robert_fekete@nymc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Fekete, MD</last_name>
    <phone>9143451313</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Terence Cardinal Cooke Health Care Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Becker, LMSW</last_name>
      <phone>212-360-3711</phone>
    </contact>
    <investigator>
      <last_name>Robert Fekete, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silky Singh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nymc.edu/neurology/fekete.htm</url>
    <description>Dr. Robert Fekete bio</description>
  </link>
  <reference>
    <citation>Fekete R, Davidson A, Ondo WG, Cohen HS. Effect of tetrabenazine on computerized dynamic posturography in Huntington disease patients. Parkinsonism Relat Disord. 2012 Aug;18(7):896-8. doi: 10.1016/j.parkreldis.2012.04.029. Epub 2012 May 22.</citation>
    <PMID>22621818</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 15, 2013</lastchanged_date>
  <firstreceived_date>April 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York Medical College</investigator_affiliation>
    <investigator_full_name>Robert Fekete</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Huntington disease</keyword>
  <keyword>HD</keyword>
  <keyword>tetrabenazine</keyword>
  <keyword>Stroop</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tetrabenazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
